Doxorubicin liposomal - GP Pharm
Alternative Names: SarcodoxomeLatest Information Update: 04 Sep 2018
Price :
$50 *
At a glance
- Originator GP Pharm
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Soft tissue sarcoma
Most Recent Events
- 04 Sep 2018 No development reported - Phase-II for Soft tissue sarcoma (First-line therapy, In the elderly) in Spain (IV)
- 14 Dec 2015 Phase II development is ongoing Spain
- 21 Dec 2006 GP Pharm's liposomal doxorubicin has received Orphan Drug Status for Soft Tissue Sarcoma in the European Union